Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study

SUMMARY: Romosozumab, a sclerostin antibody, exerts dual effect to increase bone formation and decrease bone resorption. Among high-risk postmenopausal East Asian women, romosozumab followed by alendronate was associated with lower incidences of fractures vs alendronate alone. Romosozumab demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, E. M. C., Dinavahi, R., Woo, Y. C., Wu, C.-H., Guan, J., Maddox, J., Tolman, C., Yang, W., Shin, C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075830/
https://www.ncbi.nlm.nih.gov/pubmed/32047951
http://dx.doi.org/10.1007/s00198-020-05324-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075830/
https://www.ncbi.nlm.nih.gov/pubmed/32047951
http://dx.doi.org/10.1007/s00198-020-05324-0

Ejemplares similares